Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Disease area: Airway diseases

Abstract

Respiratory bacterial infections cause exacerbation of respiratory diseases such as severe asthma and COPD, which are corticosteroid refractory, and the aim is to set up corticosteroid insensitive animal model exposed to lipopolysaccharide (LPS) and evaluate the molecular signaling. Here we show that repeated intranasal LPS challenge induced corticosteroid insensitive inflammation in mice, and a phospoinositide-3-kinase (PI3K) d inhibitor restored the corticosteroid action in that model. LPS was administrated intranasally to A/J male mice for 1-3 days, and IC87114 and/or fluticasone propionate (FP) were treated intranasally at 2 h before each LPS administration. BALF was collected at 24 h after the last LPS administration and neutrophils were quantified by FACS analysis. The level of CXCL1 in BALF was also determined using a commercially available kit. Repeated LPS exposure in contrast to single treatment showed significant increase in neutrophils and CXCL1 in BALF, which were not inhibited by FP (0.05 – 1.0 mg/ml). Phospho-Akt, a surrogate marker of PI3K activation, also increased. Although a selective PI3K d inhibitor, IC87114 (4.0 mg/ml) alone did not a show beneficial effects, combination of IC87114 and FP elicited stronger inhibition of neutrophilia and CXCL1 production. In addition, combination of theophylline (2.0 mg/ml) and FP also showed significant inhibition on the airway inflammation induced by LPS. This profile suggests that a PI3K d inhibitor with corticosteroid offers potential treatment of airway inflammation in patients with respiratory disease during bacterial infection.

Rating:

Share or cite this content

Citations should be made in the following way:
G. Kimura, K. Ueda, Y. Nishimoto, T. Masuko, T. Kusama, P. J. Barnes, K. Ito, Y. Kizawa (Funabashi, Japan; London, United Kingdom). Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling. Eur Respir J 2014; 44: Suppl. 58, 1503

Member's Comments

No comment yet.

Related content which might interest you: Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Influenza induced exacerbation is associated with steroid insensitive AHR and pulmonary inflammation in HDM-sensitised mice Source: International Congress 2016 – Immune responses in the lung Year: 2016 Effects of phosphoinositide-3-kinase inhibitors on steroid-insensitive airway inflammation in poly(I:C) and allergen challenged mice Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation Source: International Congress 2016 – Airway response to infection Year: 2016 AZD7624, an inhaled p38 inhibitor for COPD, attenuates lung and systemic inflammation after LPS Challenge in humans Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Andrographolide restores steroid sensitivity to block LPS/IFN-γ-induced IL-27 and airway hyperresponsiveness in mice Source: International Congress 2015 – New models for treating airway diseases Year: 2015 BmTI-A: A serine protease inhibitor attenuates hyperresponsiveness in an experimental model of chronic allergic inflammation in Balb/c mice Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Acid sphingomyelinase deficiency improves lung function in allergen-induced asthma in mice Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 LATE-BREAKING ABSTRACT: Effect of inhaled kinase inhibitor on airway inflammation assessed in induced sputum after challenge with inhaled lipopolysaccharide Source: International Congress 2016 – Novel mechanisms and therapeutic targets in acute and chronic inflammatory disease Year: 2016 New inhaled JAK inhibitor LAS194046 inhibits allergen-induced airway inflammation in Brown Norway rats Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Ciclesonide and tiotropium synergistically inhibit airway eosinophilia in a guinea pig model of chronic asthma Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013 Resistive breathing aggravates endotoxin-induced lung inflammation Source: International Congress 2014 – Critical illness and therapeutic interventions Year: 2014 Inhibition of JAK/STAT pathway in airway epithelium as a potential targeted therapy of asthma Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013